Entest Biomedical, Inc. CEO David Koos and MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.) CEO Thomas Ichim to Discuss Recent Announcement of Potential Business Combination

SAN DIEGO, CA--(Marketwire - April 14, 2010) - Entest BioMedical, Inc. (OTCBB: ENTB) announced that Entest CEO David Koos and Medistem CEO Thomas Ichim will be on Entest’s blogcast Thursday, April 15, 2010 at 11:00 a.m. Pacific Daylight Time (www.entestbioblog.com/live). During the blogcast, both CEOs will discuss the synergies of this potential transaction, future sources of revenue and products in the pipeline.

Entest CEO David Koos noted, “With the announcement of our intent to acquire a controlling interest in Medistem, I’ve received numerous inquires about what this transaction means for Entest shareholders. My goal for tomorrow’s blogcast is to convey to our shareholders why we are extremely excited about this transaction.”

“I believe that Medistem’s research abilities and relationships coupled with Entest’s aggressive product development approach will lead to a powerful business benefiting both companies’ shareholders,” said Thomas Ichim, CEO of Medistem.

Topics to be discussed will include: Entest’s photoceutical therapy and application to regenerative medicine, Medistem’s endometrial regenerative cell (ERC) product, synergies between the two companies’ research and product lines.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT-576™ is a proprietary laser device currently under development by Entest. The Company has filed 4 patent applications relating to the treatment of COPD. Entest BioMedical Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest announced publication of its platform technology in the peer-reviewed Journal of Translational Medicine which is available at http://www.translational-medicine.com/content/8/1/16. For additional information on Entest, go to the Company’s website: www.entestbio.com or its blog site: www.entestbioblog.com.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.